GlassScriptPhysician profile
Kathy Karamlou
NPI 1740209303
$23,063.12
in general payments reported to CMS, 2019-2025
34 companies · $5,154 in 2025
The $5,154 reported for 2025 was more than what 86% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,837 · 2020: $863 · 2021: $1,984 · 2022: $4,913 · 2023: $3,770 · 2024: $4,542 · 2025: $5,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,160 · Consulting Fee: $6,050 · Education: $174 · Travel and Lodging: $82.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,159.81 |
| Consulting Fee | $6,050.00 |
| Education | $173.99 |
| Travel and Lodging | $82.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $7,885.58 | 2019-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $3,013.89 | 2019-2025 | |
| Kyowa Kirin, INC. | $1,956.92 | 2023-2024 | Crysvita |
| Ucb, INC. | $1,508.55 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,324.52 | 2019-2025 | |
| Lilly USA, LLC | $1,323.03 | 2019-2025 | Taltz, Zepbound |
| Amgen INC. | $1,282.70 | 2019-2025 | Uplizna, Otezla, Evenity |
| Glaxosmithkline, LLC. | $752.47 | 2019-2024 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $599.18 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $451.42 | 2019-2022 | |
| Pfizer INC. | $411.87 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.98 | 2020-2025 | Ofev, Cyltezo |
| Sobi, INC | $296.57 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $285.00 | 2019-2024 | |
| Genzyme Corporation | $250.53 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $224.68 | 2021-2025 | Hadlima, Renflexis |
| Mallinckrodt Hospital Products INC. | $195.56 | 2024-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $170.46 | 2023-2025 | Strensiq |
| Octapharma USA, INC. | $148.11 | 2021-2023 | Octagam Immune Globulin (Human) |
| Radius Health, INC. | $139.37 | 2022-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $128.86 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $69.76 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $60.51 | 2019-2020 | |
| Celgene Corporation | $41.80 | 2019 | |
| Genentech USA, INC. | $41.03 | 2019-2023 | Actemra |
| Fresenius Kabi USA, LLC | $34.22 | 2024 | |
| Eusa Pharma (US) LLC | $23.56 | 2021 | |
| Oxford Immunotec USA INC | $20.39 | 2022 | |
| Csl Behring | $19.22 | 2022 | |
| Mallinckrodt Enterprises LLC | $18.72 | 2019 | |
| Gilead Sciences, INC. | $16.21 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.94 | 2021 | |
| Merck Sharp & Dohme LLC | $13.84 | 2019 | |
| Grifols USA, LLC | $13.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Karamlou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.